# Celecoxib Capsules

Canonical: https://abierto.us/opportunities/spe2d225r0021

- Solicitation number: SPE2D2-25-R-0021
- Notice type: Award notice (first published as presolicitation)
- Status: Awarded to Radha Pharmaceuticals Inc. for $15,771,598.00
- Department: Department of Defense
- Agency: Defense Logistics Agency
- Contracting office: DLA Troop Support (SPE2D2)
- NAICS: 325412 Pharmaceutical Preparation Manufacturing
- Product or service code: 6505 Drugs and Biologicals
- Place of performance: Hauppauge, New York
- County: Suffolk County (FIPS 36103). https://abierto.us/counties/suffolk-county-ny-36103
- City: Hauppauge. https://abierto.us/cities/hauppauge-ny-3632732
- First posted: July 31, 2025
- Last posted: March 19, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/da23bd0b326b419caa0e7a99495ddfa2/view

## Description

SPE2D2-26-D-0010 Celecoxib Capsules

## Award on USAspending

- Recipient: Radha Pharmaceuticals Inc. (UEI C1S5SQ88KY67)
- Contract: SPE2D226D0010
- Obligated: $0.00
- Competition: Full and Open Competition, 1 offers received
- Link: award number SPE2D226D0010 equals the contract number; same awarding office SPE2D2 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_IDV_SPE2D226D0010_9700/


## Publications

- July 31, 2025: Presolicitation. Notice 6b9c41e3a05c44808010baaa4cde09cd. https://sam.gov/workspace/contract/opp/6b9c41e3a05c44808010baaa4cde09cd/view
- August 26, 2025: Solicitation, due September 25, 2025 at 3:00 PM EDT. Notice 418dab78c1cb45b8b96f84233ab00518. https://sam.gov/workspace/contract/opp/418dab78c1cb45b8b96f84233ab00518/view
- March 19, 2026: Award notice. Notice da23bd0b326b419caa0e7a99495ddfa2. https://sam.gov/workspace/contract/opp/da23bd0b326b419caa0e7a99495ddfa2/view

## Points of contact

- Ryan Guarnere, ryan.guarnere@dla.mil, 445-737-1729
- Jason Wray, jason.wray@dla.mil, 445-737-6304

---
Source: SAM.gov Contract Opportunities bulk extract and USAspending.gov award data. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/spe2d225r0021.